Press Releases

Date Title and Summary View
Toggle Summary New Monthly Series Spotlights What 100 Physicians Find to be Critical Needs in Their Battle Against COVID-19
The first survey results reveal physicians seek new diagnostic tools and insights to improve COVID-19 management and patient outcomes OXFORD, United Kingdom and MARLBOROUGH, Mass., Jan. 14, 2021 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq: OXFD) (the “Company”), a global, high-growth
View HTML
Toggle Summary Oxford Immunotec’s T-SPOT® Discovery SARS-CoV-2 Test is Used to Measure the Efficacy of Valneva’s VLA2001 COVID-19 Vaccine Candidate in a Phase I/II Clinical Study
OXFORD, United Kingdom and MARLBOROUGH, Mass., Jan. 13, 2021 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq: OXFD) (the “Company”), a global, high-growth diagnostics company, announce the start of a collaboration with Valneva. The Company will perform T cell testing on participants
View HTML
Toggle Summary PerkinElmer to Acquire Oxford Immunotec Global PLC
PerkinElmer to acquire Oxford Immunotec for USD 22.00 per share in cash Transaction expected to be completed in the first half of 2021 WALTHAM, Mass. & LONDON --(BUSINESS WIRE)--Jan. 7, 2021-- PerkinElmer, Inc. (NYSE: PKI) (“ PerkinElmer ”) and Oxford Immunotec Global PLC (NASDAQ: OXFD) (" Oxford
View HTML
Toggle Summary Oxford Immunotec Announces the Foundation of the Global T Cell Expert Consortium, Whose First Meeting Took Place This Week
OXFORD, United Kingdom and MARLBOROUGH, Mass., Dec. 16, 2020 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq: OXFD) (the “Company”), a global, high-growth diagnostics company, announce the formation and initial meeting of the Global T cell expert consortium (GTEC).
View HTML
Toggle Summary Oxford Immunotec Announces the Approval of the T-Cell Select™ Reagent Kit, Used to Automate the T-SPOT®.TB Test Workflow, for IVD Use in South Korea
OXFORD, United Kingdom and MARLBOROUGH, Mass., Dec. 10, 2020 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq: OXFD) (the “Company”), a global, high-growth diagnostics company today announced that the Company’s T-Cell Select reagent kit has been approved for use by the Ministry of Food and
View HTML
Toggle Summary Oxford Immunotec Signs Exclusive Distributor Agreement with RIKEN Genesis, a Subsidiary of Sysmex, to Market the T-SPOT® Discovery SARS-CoV-2 Kit for the Measurement of the T cell Immune Response to SARS-CoV-2 Infection in Japan
OXFORD, United Kingdom and MARLBOROUGH, Mass., Dec. 02, 2020 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq: OXFD) (the “Company”), a global, high-growth diagnostics company today announces it has entered into an exclusive distribution agreement with RIKEN Genesis Co., Ltd, a subsidiary of
View HTML
Toggle Summary Oxford Immunotec to Hold a Virtual Investor Event on December 17, 2020
OXFORD, United Kingdom and MARLBOROUGH, Mass., Nov. 23, 2020 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD) (the "Company"), a global, high-growth diagnostics company, today announced that it plans to hold a virtual investor event on Thursday, December 17, 2020. Dr.
View HTML
Toggle Summary Data Showing SARS-CoV-2 Reactive T Cells are Associated with Protection from COVID-19 – and Can Be Both Detected and Measured Using Oxford Immunotec’s T-SPOT® Technology – is Published by Public Health England and Oxford Immunotec
OXFORD, United Kingdom and MARLBOROUGH, Mass., Nov. 10, 2020 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq: OXFD) (the “Company”), a global, high-growth diagnostics company, today announced the release of data from a prospective cohort study in keyworkers in the UK – a collaboration
View HTML
Toggle Summary Oxford Immunotec Files Submission to Food and Drug Administration (FDA) for the T-Cell Select™ Reagent Kit
If approved, the T-Cell Select reagent kit would enable automated sample preparation and the T-SPOT ® .TB test to be used with blood samples stored for up to 54 hours at room temperature OXFORD, United Kingdom and MARLBOROUGH, Mass., Nov. 05, 2020 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC
View HTML
Toggle Summary Oxford Immunotec Reports Third Quarter 2020 Financial Results
Third quarter revenue of $ 19.4 million, above guidance of range of $18 - $ 19 million Asia-Pacific region returns to g r owth and sets a new quarterly sales record for the region Europe & rest of world and U.S. regions recover strongly from low point in the second quarter Gross Margin of 76.4%
View HTML